Hematopoietic Stem Cell Transplantation Activity in China 2020–2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group

Xu, Lei; Lu, Dao‐Pei; Wu, Depei; Jiang, Erlie; Liu, Dai‐Hong; Huang, He; Sun, Zimin; Li, Nai-Nong; Liu, Qifa; Zhang, Xi; Lai, Yongrong; Song, Yongping; Song, Xianmin; Liu, Sixi; Zhang, Yicheng; Luo, Chengjuan; Xia, Linghui; Niu, Ting; Yu, Yu; Zhang, Xiao-Hui; Tang, Xiaowen; Luo, Yi; Huang, Xiao‐Jun

doi:10.1016/j.jtct.2022.11.011

Cited by 14 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, during the crisis, international bone marrow donor centers faced an international traffic perturbation which may have contributed to an increase in the use domestic donors [37% vs 22% in the Deutsche Knochenmarkspenderdatei (DKMS) report (30)], easier to manage. Despite the fact that there was no difference in the United States study (28), the two European studies (27,29) reported a higher number of haplo-identical transplants (an increase from 6.2% to 12%), with similar results in Chinese studies (32,33). Although a family donor may be easier to manage, with more certainty about the success of stem cell collection, this increase may also be explained by better knowledge of haploidentical transplantation and better prevention of GVHD thanks to post-transplant cyclophosphamide (PTCy).…”

Section: An Evolving High-risk Diseasementioning

confidence: 82%

Allogeneic hematopoietic stem cell transplantation in the COVID-19 era

Bordat

Maury²,

Leclerc³

2023

Front. Immunol.

View full text Add to dashboard Cite

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) recipients are especially vulnerable to coronavirus disease 19 (COVID-19), because of their profound immunodeficiency. Indeed, the first pandemic wave was marked by a high mortality rate in this population. Factors increasing immunodepression such as older age, immunosuppressive treatments or a short delay between transplant and infection appear to worsen the prognosis. Many changes in clinical practice had to be implemented in order to limit this risk, including postponing of transplant for non-malignant diseases, preference for local rather than international donations and for peripheral blood as stem cell source, and the widespread use of cryopreservation. The great revolution in the COVID-19 pandemic came from the development of mRNA vaccines that have shown to be able to prevent severe forms of the disease. More than 75% of allo-HSCT recipients develop seroconversion after 2 doses of vaccine. Multiple studies have identified lymphopenia, exposure to immunosuppressive or anti-CD20 therapies, and a short post-transplant period as factors associated with a poor response to vaccination. The use of repeated injections of the vaccine, including a third dose, not only improves the seroconversion rate but also intensifies the immune response, both in B cells and T cells. Vaccines are an effective and well-tolerated method in this high-risk population. Some studies investigated the possibility of immune protection being transferred from a vaccinated donor to a recipient, with encouraging initial results. However, dynamic mutations and immune escape of the virus can lead to breakthrough infections with new variants in vaccinated individuals and still represent a threat of severe disease in allo-HSCT recipients. New challenges include the need to adapt vaccine protection to emerging variants.

show abstract

Section: An Evolving High-risk Diseasementioning

confidence: 82%

Allogeneic hematopoietic stem cell transplantation in the COVID-19 era

Bordat

Maury²,

Leclerc³

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In addition, most of the studies only enrolled matched sibling donors (MSDs) as HSCT recipients. 10,11,14 Since 2000s, haploidentical related donors (HIDs) have been widely applied in allo-HSCT [18][19][20][21][22][23][24] which have become the most important alternative donor in China. 18 Several studies reported that the clinical outcomes were comparable between HIDs and MSDs HSCT recipients in different haematological malignancies (e.g.…”

Section: Introductionmentioning

confidence: 99%

Allogeneic haematopoietic stem cell transplantation for adult T‐lymphoblastic lymphoma: A real‐world multicentre analysis in China

Huo,

Gao,

Song

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryIn this multicentre, real‐world study, we aimed to identify the clinical outcomes and safety of allogeneic haematopoietic stem cell transplantation (allo‐HSCT) in T‐lymphoblastic lymphoma (T‐LBL). A total of 130 Ann Arbor stage III or IV T‐LBL patients (>16 years) treated with allo‐HSCT across five transplant centres were enrolled. The 2‐year cumulative incidence of disease progression, the probabilities of progression‐free survival (PFS), overall survival (OS) and non‐relapse mortality (NRM) after allo‐HSCT were 21.0%, 69.8%, 79.5% and 9.2% respectively. Patients with central nervous system (CNS) involvement had a higher cumulative incidence of disease progression compared with those without CNS involvement (57.1% vs. 18.9%, HR 3.78, p = 0.014). Patients receiving allo‐HSCT in non‐remission (NR) had a poorer PFS compared with those receiving allo‐HSCT in complete remission (CR) or partial remission (49.2% vs. 72.7%, HR 2.21, p = 0.041). Particularly for patients with bone marrow involvement and achieving CR before allo‐HSCT, measurable residual disease (MRD) positivity before allo‐HSCT was associated with a poorer PFS compared with MRD negativity (62.7% vs. 86.8%, HR 1.94, p = 0.036). On multivariate analysis, CNS involvement at diagnosis and receiving allo‐HSCT in NR were associated with disease progression. Thus, our real‐world data suggested that allo‐HSCT appeared to be an effective therapy for adult T‐LBL patients with Ann Arbor stage III or IV disease.

show abstract

“…However, allogeneic hematopoietic stem cell transplantation (allo-SCT) cannot be delayed for patients with haematological malignancies, especially acute leukaemias, with a very high-risk of relapse. Maintaining safe haematopoietic stem cell donations from related or unrelated donors appeared imminently mandatory [ 2 , 17 ]. For unrelated donors, transplant centres and registries had to solve many challenges, such as the graft traveling and SARS-CoV2 testing [15] .…”

Section: Introductionmentioning

confidence: 99%